Susquehanna International Group
ENTA icon

Susquehanna International Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Susquehanna International Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$179K Buy
14,208
+3,741
+36% +$50.1K ﹤0.01% 11807
2025
Q4 		$165K Sell
10,467
-106,837
-91% -$1.36M ﹤0.01% 11071
2025
Q3 		$1.4M Buy
117,304
+43,545
+59% +$348K ﹤0.01% 6545
2025
Q2 		$558K Buy
73,759
+37,106
+101% +$223K ﹤0.01% 8917
2025
Q1 		$202K Buy
36,653
+24,437
+200% +$151K ﹤0.01% 10908
2024
Q4 		$70.2K Buy
+12,216
New +$117K ﹤0.01% 11537
2024
Q2 		– Sell
-18,005
Closed -$314K – 12297
2024
Q1 		$314K Sell
18,005
-61,657
-77% -$816K ﹤0.01% 9610
2023
Q4 		$750K Sell
79,662
-8,893
-10% -$82.9K ﹤0.01% 7697
2023
Q3 		$989K Buy
88,555
+76,127
+613% +$1.23M ﹤0.01% 6652
2023
Q2 		$266K Sell
12,428
-26,358
-68% -$777K ﹤0.01% 9682
2023
Q1 		$1.57M Buy
38,786
+30,293
+357% +$1.45M ﹤0.01% 5697
2022
Q4 		$395K Sell
8,493
-14,515
-63% -$662K ﹤0.01% 8419
2022
Q3 		$1.19M Buy
23,008
+18,115
+370% +$1.06M ﹤0.01% 6180
2022
Q2 		$231K Sell
4,893
-10,344
-68% -$561K ﹤0.01% 10267
2022
Q1 		$1.08M Sell
15,237
-8,129
-35% -$529K ﹤0.01% 6904
2021
Q4 		$1.75M Buy
23,366
+9,973
+74% +$783K ﹤0.01% 5830
2021
Q3 		$761K Sell
13,393
-3,459
-21% -$171K ﹤0.01% 8269
2021
Q2 		$742K Sell
16,852
-4,050
-19% -$198K ﹤0.01% 8588
2021
Q1 		$1.03M Sell
20,902
-5,633
-21% -$281K ﹤0.01% 7662
2020
Q4 		$1.12M Buy
+26,535
New +$1.17M ﹤0.01% 6463
2020
Q3 		– Sell
-7,097
Closed -$344K – 10664
2020
Q2 		$356K Sell
7,097
-6,742
-49% -$349K ﹤0.01% 8041
2020
Q1 		$712K Buy
+13,839
New +$738K ﹤0.01% 6148
2019
Q4 		– Sell
-23,637
Closed -$1.47M – 9914
2019
Q3 		$1.42M Sell
23,637
-42,984
-65% -$3.19M ﹤0.01% 4939
2019
Q2 		$5.62M Buy
+66,621
New +$5.99M ﹤0.01% 2560
2018
Q3 		– Sell
-8,993
Closed -$901K – 9457
2018
Q2 		$1.04M Buy
8,993
+957
+12% +$95.5K ﹤0.01% 5260
2018
Q1 		$650K Buy
+8,036
New +$618K ﹤0.01% 6114
2017
Q3 		– Sell
-71,815
Closed -$2.89M – 8990
2017
Q2 		$2.58M Buy
+71,815
New +$2.3M ﹤0.01% 3423
2016
Q2 		– Sell
-37,395
Closed -$979K – 8703
2016
Q1 		$1.1M Buy
37,395
+9,326
+33% +$260K ﹤0.01% 4895
2015
Q4 		$927K Sell
28,069
-6,171
-18% -$201K ﹤0.01% 5563
2015
Q3 		$1.24M Buy
34,240
+21,534
+169% +$925K ﹤0.01% 5248
2015
Q2 		$572K Sell
12,706
-17,212
-58% -$670K ﹤0.01% 7354
2015
Q1 		$916K Sell
29,918
-35,109
-54% -$1.37M ﹤0.01% 5922
2014
Q4 		$3.31M Buy
65,027
+39,346
+153% +$1.76M ﹤0.01% 3565
2014
Q3 		$1.02M Buy
25,681
+16,877
+192% +$673K ﹤0.01% 5889
2014
Q2 		$379K Buy
8,804
+3,452
+64% +$132K ﹤0.01% 7982
2014
Q1 		$214K Buy
+5,352
New +$194K ﹤0.01% 8129

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna International Group's ENTA Position: Q1 2026 in Review

Susquehanna International Group increased its Enanta Pharmaceuticals (ENTA) stake by 36% in Q1 2026, buying an estimated $50.1K and bringing the position to 14,208 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #11807.

Susquehanna International Group first reported a position in ENTA in Q1 2014 and has held it in 36 quarters since. The position peaked at $5.62M in Q2 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Susquehanna International Group held 14,208 shares of Enanta Pharmaceuticals worth $179K as of Q1 2026.
  • Susquehanna International Group bought 3,741 Enanta Pharmaceuticals shares in Q1 2026, an estimated $50.1K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11807 holding.
  • Susquehanna International Group first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 36 quarters since.
  • Susquehanna International Group's Enanta Pharmaceuticals position peaked at $5.62M in Q2 2019.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.